Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02252835
Recruitment Status : Completed
First Posted : September 30, 2014
Last Update Posted : April 17, 2015
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.

Brief Summary:
The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics, safety and potential for drug-drug interaction of arhalofenate when combined with febuxostat in adult population with gout.

Condition or disease Intervention/treatment Phase
Gout Hyperuricemia Drug: Arhalofenate Drug: Febuxostat Drug: Colchicine Phase 2

Detailed Description:
Patients entering the six-week Treatment Period will receive once daily oral dosing of arhalofenate during Weeks 1 and 2 (Days 1 through 14), combined once daily oral dosing of arhalofenate and febuxostat during Weeks 3 and 4 (Days 15 through 28), and once daily oral dosing of febuxostat during Weeks 5 and 6 (Days 29 through 42). In addition, all patients will receive once daily oral dosing of colchicine throughout the Treatment Period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
Study Start Date : August 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout
MedlinePlus related topics: Gout
Drug Information available for: Febuxostat

Arm Intervention/treatment
Experimental: Arhalofenate with febuxostat (PK cohort) Drug: Arhalofenate
800 mg once daily orally for four weeks

Drug: Febuxostat
40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks

Drug: Colchicine
0.6 mg daily

Experimental: Arhalofenate with febuxostat (non-PK cohort) Drug: Arhalofenate
600 mg once daily orally for four weeks

Drug: Febuxostat
80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks

Drug: Colchicine
0.6 mg daily




Primary Outcome Measures :
  1. Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL on Day 29 after treatment with arhalofenate 800 mg and febuxostat 80 mg [ Time Frame: Day 29 ]
  2. Proportion of patients achieving an sUA reduction of ≥ 2.0, ≥ 3.0, and ≥ 4.0 mg/dL from baseline on Day 29 after treatment with arhalofenate 800 mg and febuxostat 80 mg [ Time Frame: Day 29 ]
  3. Absolute and percent reduction in sUA from baseline on Day 29 after treatment with arhalofenate 800 mg and febuxostat 80 mg [ Time Frame: Day 29 ]
  4. AUC(0-t) of arhalofenate 800 mg and febuxostat 80 mg when administered separately and in combination [ Time Frame: Days 14, 28, and 42 ]
  5. AUC(0-tau) of arhalofenate 800 mg and febuxostat 80 mg when administered separately and in combination [ Time Frame: Days 14, 28, and 42 ]
  6. Tmax of arhalofenate 800 mg and febuxostat 80 mg when administered separately and in combination [ Time Frame: Days 14, 28, and 42 ]
  7. Cmax of arhalofenate 800 mg and febuxostat 80 mg when administered separately and in combination [ Time Frame: Days 14, 28, and 42 ]

Secondary Outcome Measures :
  1. Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL on Day 29 after treatment with arhalofenate 600 mg and febuxostat 40 mg [ Time Frame: Day 29 ]
  2. Proportion of patients achieving an sUA reduction of ≥ 2.0, ≥ 3.0, and ≥ 4.0 mg/dL from baseline on Day 29 after treatment with arhalofenate 600 mg and febuxostat 40 mg [ Time Frame: Day 29 ]
  3. Absolute and percent reduction in sUA from baseline on Day 29 after treatment with arhalofenate 600 mg and febuxostat 40 mg [ Time Frame: Day 29 ]
  4. Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL on Day 22 after treatment with arhalofenate 800 mg and febuxostat 40 mg, and with arhalofenate 600 mg and febuxostat 80 mg [ Time Frame: Day 22 ]
  5. Proportion of patients achieving an sUA reduction of ≥ 2.0, ≥ 3.0, and ≥ 4.0 mg/dL from baseline on Day 22 after treatment with arhalofenate 800 mg and febuxostat 40 mg, and with arhalofenate 600 mg and febuxostat 80 mg [ Time Frame: Day 22 ]
  6. Absolute and percent reduction in sUA from baseline on Day 22 after treatment with arhalofenate 800 mg and febuxostat 40 mg, and with arhalofenate 600 mg and febuxostat 80 mg [ Time Frame: Day 22 ]
  7. Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL after monotherapy treatment with arhalofenate 600 or 800 mg, or febuxostat 40 or 80 mg [ Time Frame: Day 15 or Day 43 ]
  8. Proportion of patients achieving an sUA reduction of ≥ 2.0, ≥ 3.0, and ≥ 4.0 mg/dL from baseline after monotherapy treatment with arhalofenate 600 or 800 mg, or febuxostat 40 or 80 mg [ Time Frame: Day 15 or Day 43 ]
  9. Absolute and percent reduction in sUA from baseline on Day 15 after monotherapy treatment with arhalofenate 600 or 800 mg [ Time Frame: Day 15 ]
  10. Absolute and percent reduction in sUA from baseline on Day 43 after monotherapy treatment with febuxostat 40 or 80 mg [ Time Frame: Day 43 ]
  11. Kel and T1/2 of arhalofenate 800 mg and febuxostat 80 mg, if possible, when administered separately and in combination [ Time Frame: Days 14, 28, and 42 ]

Other Outcome Measures:
  1. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Days 1 through 43 ]
  2. Change in physical examination findings [ Time Frame: Days 1 through 43 ]
  3. Change in vital signs and safety laboratory tests [ Time Frame: Days 1 through 43 ]
  4. Safety-related study drug discontinuations [ Time Frame: Days 1 through 43 ]
  5. Deaths [ Time Frame: Days 1 through 43 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patient, 18 to 75 years of age, inclusive
  • Known gout diagnosis (per criteria of the American Rheumatism Association)
  • Has an sUA ≥ 7.5 mg/dL
  • A female patient must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least two years), or must agree to use two medically accepted methods of contraception including a barrier method for the entire duration of study participation unless she reports compete sexual abstinence. A female patient must also not be pregnant or lactating
  • Estimated creatinine clearance (eCrCl) ≥ 60 ml/min, as calculated by Cockcroft-Gault method
  • ALT or AST ≤ 3 times upper limit of normal (ULN) or total bilirubin ≤ 2 times ULN (Gilbert's syndrome is permitted)
  • All other clinical laboratory parameters must be within normal limits or considered not clinically significant
  • ECG must be normal, or if abnormal, considered not clinically significant
  • A patient who is taking a medication or agent (other than a ULT) known to influence sUA levels must be on a stable dose and regimen of the medication for at least two weeks prior to screening and must be willing to continue the same dose and regimen during study participation
  • Expected to be able to tolerate a short course of oral NSAIDs and/or oral steroids as may be needed to treat a gout flare
  • Must be able to swallow tablets

Exclusion Criteria:

  • Treatment with any ULT (e.g., allopurinol, febuxostat, probenecid, or benzbromarone) within two weeks, or pegloticase within six months, prior to the sUA assessment at Day 1
  • Occurrence of a gout flare that has not resolved within one week prior to Day 1
  • Known or suspected secondary hyperuricemia (e.g., due to myeloproliferative disorder or organ transplant)
  • Diagnosis of xanthinuria
  • Fractional excretion of urate > 10%
  • History of documented or suspected kidney stones within five years prior to screening
  • Known infection with the human immunodeficiency virus (HIV) or history of hepatitis B or C
  • Recent use/abuse of an illicit drug as determined by a positive urine drug screen
  • Uncontrolled hypertension that, in the opinion of the Investigator, would preclude participation in the study
  • History of stroke, transient ischemic attack, acute myocardial infarction, congestive heart failure (NYHA class II - IV), angina pectoris, coronary intervention procedure, lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within 5 years of screening
  • History of cancer within five years of screening, with the following exceptions: adequately treated non-melanoma skin cancer, non-metastatic prostate cancer, or in situ cervical cancer
  • Body mass index (BMI) > 42 kg/m2
  • Current or expected requirement for anticoagulant therapy, except for low dose (≤ 81 mg/day) aspirin, clopidogrel (Plavix) ≤ 75 mg/day, or prasugrel (Effient) ≤ 10 mg/day
  • Use of any of the following within eight weeks prior to screening: potent CYP3A4 inhibitors, cytotoxic agents (including azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.), ranolazine, digoxin, theophylline, sulphonylureas, thiazolidinediones (e.g., rosiglitazone or pioglitazone), desipramine, atypical antipsychotic agents, loop diuretics, warfarin, or phenytoin
  • Chronic treatment with NSAIDs that cannot be safely discontinued-term use of NSAIDs is permitted, e.g., when used to treat gout flares
  • Known hypersensitivity or intolerance to febuxostat or colchicine
  • Treatment with any other investigational therapy within 30 days or within five half-lives, whichever is longer prior to Day 1
  • Any other condition that would compromise the safety of the patient, prevent compliance with the study protocol, or compromise the quality of the clinical study, as judged by the Investigator and/or Medical Monitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02252835


Locations
Layout table for location information
United States, Kansas
Vince & Associates Clinical Research
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
CymaBay Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Alexandra Steinberg, MD, PhD CymaBay Therapeutics, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02252835     History of Changes
Other Study ID Numbers: CB102-21426
First Posted: September 30, 2014    Key Record Dates
Last Update Posted: April 17, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Febuxostat
Gout
Hyperuricemia
Arthritis
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Pathologic Processes
Colchicine
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents